A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
Inclusion Criteria:
Exclusion Criteria:
- Participants must not have experienced or be recovering from a clinical MS relapse within 6 months of Screening.
Berkeley, California 94705-2017, United States
Carlsbad, California 92011-4213, United States
Lutherville, Maryland 21093-6016, United States
Farmington Hills, Michigan 48334, United States
Owosso, Michigan 48867-2116, United States
Chaska, Minnesota 55318-4551, United States
St Louis, Missouri 63131-2322, United States
Houston, Texas 77030-1501, United States
Seattle, Washington 98133-8400, United States
Vancouver, British Columbia V6T 1Z3, Canada
London, Ontario N6A 5A5, Canada